← Back to Search

MEK Inhibitor

AZD6244 for Advanced Cancer

Phase 1
Waitlist Available
Research Sponsored by AstraZeneca
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
cancer which is refractory to standard therapies
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up assessed at each visit
Awards & highlights

Study Summary

This trial will study the effects of a new drug called AZD6244 on patients with advanced cancer. They will be testing to see if the drug is safe and tolerable for patients.

Who is the study for?
This trial is for adults with advanced solid tumors that haven't responded to standard treatments. Participants should be relatively active and mobile (WHO performance status 0-2), not pregnant, and must not have had recent chemotherapy or radiotherapy. Those with severe diseases or brain complications are excluded.Check my eligibility
What is being tested?
The study is testing the safety and how the body processes a capsule form of AZD6244, a potential new cancer treatment. It's aimed at patients whose cancers have stopped responding to usual treatments.See study design
What are the potential side effects?
While specific side effects aren't listed here, common ones for cancer drugs like AZD6244 may include nausea, vomiting, diarrhea, skin rash, fatigue, liver enzyme changes, and blood count fluctuations.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
Your cancer has not responded to standard treatments.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~each visit
This trial's timeline: 3 weeks for screening, Varies for treatment, and each visit for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
To assess the pharmacokinetics of the solid dose form of AZD6244
Secondary outcome measures
To assess safety and tolerability of solid dose form of AZD6244

Side effects data

From 2020 Phase 2 trial • 334 Patients • NCT01248247
50%
Rash Acneiform
36%
Diarrhea
32%
Nausea
32%
Dry skin
27%
Anorexia
23%
Increased blood bilirubin
23%
Vomiting
23%
Increased AST
14%
Oral mucositis
14%
Weight loss
14%
Other skin and subcutaneous tissue disorders, specify
14%
Rash Maculopapular
14%
Epistaxis
9%
Fatigue
9%
Hyperglycemia
9%
Increased alkaline phosphatase
5%
Dry mouth
5%
Lung infection
5%
Pruritus
5%
Hyponatremia
5%
Dyspnea
5%
Palmar-plantar erythrodysesthesia syndrome
5%
Multi-organ failure
5%
Hypoalbuminemia
5%
Dysgeusia
100%
80%
60%
40%
20%
0%
Study treatment Arm
Arm 1 - Erlotinib
Arm 3 - AZD6244 + MK-2206
Arm 4 - Sorafenib
Arm 2 - Erlotinib + MK-2206

Trial Design

1Treatment groups
Experimental Treatment
Group I: AZD6244Experimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
AZD6244
2011
Completed Phase 2
~1570

Find a Location

Who is running the clinical trial?

AstraZenecaLead Sponsor
4,238 Previous Clinical Trials
288,471,363 Total Patients Enrolled
Emerging Oncology Medical Science Director, MDStudy DirectorAstraZeneca
4 Previous Clinical Trials
284 Total Patients Enrolled

Media Library

AZD6244 (MEK Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT00463814 — Phase 1
Cancer Research Study Groups: AZD6244
Cancer Clinical Trial 2023: AZD6244 Highlights & Side Effects. Trial Name: NCT00463814 — Phase 1
AZD6244 (MEK Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00463814 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has AZD6244 attained the necessary regulatory clearance for general use?

"The safety of AZD6244 is rated a 1, as this initial trial has only provided limited evidence for safety and efficacy."

Answered by AI

Are individuals aged under 50 capable of joining this medical experiment?

"This clinical trial is looking for individuals aged 18-99, with 368 studies dedicated to minors and 2609 trials targeting the elderly."

Answered by AI

What prerequisites should prospective participants of this trial meet?

"To be eligible for this medical trial, participants must have some form of malignancy and fall between the ages of 18 to 99 years old. This research project is recruiting a total population size of 58 patients."

Answered by AI

How many individuals have signed up for this experiment?

"This research project is no longer recruiting. It was posted on March 8th 2007 and last updated August 31st 2022. For those searching for other trials, there are 2820 studies admitting participants with malignancies, with 34 of them offering AZD6244 as an intervention."

Answered by AI

Are recruitment efforts still underway for this clinical exploration?

"According to clinicaltrials.gov, this research project is not presently accepting participants; the first posting was on March 8th 2007 with a final update made in August 31st 2022. Nevertheless, there are 2854 other trials currently focusing on patient recruitment."

Answered by AI

Could you please provide details on past experiments that have been done with AZD6244?

"Currently, 34 AZD6244 clinical trials are taking place and 5 of them have reached the final stage. While Philadelphia is home to a significant number of these studies, there are 1,005 sites worldwide examining this drug's efficacy."

Answered by AI

Is this research a groundbreaking innovation in the field?

"Since 2007, AstraZeneca has been researching AZD6244 with the first trial involving 58 participants. Subsequently, this medication was approved for Phase 1 and there are currently 34 active trials in 33 countries across 156 cities."

Answered by AI
~3 spots leftby Mar 2025